Biomarkers in use from these pathways include FOXO1 within the VEGF pathway, as a prognostic marker in rhabdomyosarcoma (as a fusion gene with PAX3 [59]) and also shown to be highly expressed in the infancy cluster of increased gene expression (Additional file 1: Table S2). Here, FOXO1 is linked to rhabdomyosarcoma.